Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Authors
Shaw, AKim, D
Nakagawa, K
Seto, T
Crinó, L
Ahn, M
De Pas, T
Besse, B
Solomon, B
Blackhall, Fiona H
Wu, Y
Thomas, M
O'Byrne, K
Moro-Sibilot, D
Camidge, D
Mok, T
Hirsh, V
Riely, G
Iyer, S
Tassell, V
Polli, A
Wilner, K
Jänne, P
Affiliation
Massachusetts General Hospital, Boston, MA 02114, USA. ashaw1@partners.orgIssue Date
2013-06-20
Metadata
Show full item recordAbstract
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown.Citation
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013, 368 (25):2385-94 N Engl J MedJournal
New England Journal of MedicineDOI
10.1056/NEJMoa1214886PubMed ID
23724913Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1214886
Scopus Count
Collections
Related articles
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
- Authors: Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators
- Issue date: 2014 Dec 4
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
- Authors: Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E
- Issue date: 2017 Jul
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
- Authors: Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators
- Issue date: 2017 Aug 31
- FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
- Authors: Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R
- Issue date: 2014 Oct
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
- Authors: Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T
- Issue date: 2017 Jul 1